93 related articles for article (PubMed ID: 9413164)
1. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.
Dorai T; Goluboff ET; Olsson CA; Buttyan R
Anticancer Res; 1997; 17(5A):3307-12. PubMed ID: 9413164
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
4. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
Dorai T; Olsson CA; Katz AE; Buttyan R
Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme.
Luzi E; Papucci L; Schiavone N; Donnini M; Lapucci A; Tempestini A; Witort E; Nicolin A; Capaccioli S
Cancer Gene Ther; 2003 Mar; 10(3):201-8. PubMed ID: 12637941
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector.
Gibson SA; Pellenz C; Hutchison RE; Davey FR; Shillitoe EJ
Clin Cancer Res; 2000 Jan; 6(1):213-22. PubMed ID: 10656452
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
Bruckheimer EM; Kyprianou N
Prostate; 2002 Oct; 53(2):133-42. PubMed ID: 12242728
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells.
Huang YW; Wang LS; Chang HL; Ye W; Dowd MK; Wan PJ; Lin YC
Anticancer Res; 2006; 26(3A):1925-33. PubMed ID: 16827126
[TBL] [Abstract][Full Text] [Related]
11. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
[TBL] [Abstract][Full Text] [Related]
13. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
Liu XH; Yao S; Kirschenbaum A; Levine AC
Cancer Res; 1998 Oct; 58(19):4245-9. PubMed ID: 9766645
[TBL] [Abstract][Full Text] [Related]
14. Ribozyme-mediated inhibition of PKCalpha sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis.
Orlandi L; Binda M; Folini M; Bearzatto A; Villa R; Daidone MG; Zaffaroni N
Prostate; 2003 Feb; 54(2):133-43. PubMed ID: 12497586
[TBL] [Abstract][Full Text] [Related]
15. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
16. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
Pennati M; Binda M; Colella G; Zoppe' M; Folini M; Vignati S; Valentini A; Citti L; De Cesare M; Pratesi G; Giacca M; Daidone MG; Zaffaroni N
Oncogene; 2004 Jan; 23(2):386-94. PubMed ID: 14724567
[TBL] [Abstract][Full Text] [Related]
17. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
Davies G; Watkins G; Mason MD; Jiang WG
Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
[TBL] [Abstract][Full Text] [Related]
18. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells.
Dorai T; Perlman H; Walsh K; Shabsigh A; Goluboff ET; Olsson CA; Buttyan R
Int J Cancer; 1999 Sep; 82(6):846-52. PubMed ID: 10446452
[TBL] [Abstract][Full Text] [Related]
19. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
20. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
